Conditions: Age Related Macular Degeneration
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 24
Healthy volunteers: no

Brief summary:
The Ranibizumab in Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration (RIP) Study is a prospective, multicenter, uncontrolled, interventional phase 2 clinical trial that investigates the effect of fixed monthly intravitreal injections of ranibizumab (Lucentis, Novartis Pharma, Germany) on visual acuity and retinal morphology over a study period of 12 months in 30 patients.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Ranibizumab (Lucentis, Novartis Pharma GmbH, Germany)
Intervention descriptions: intervention 1: Monthly intravitreal injections

Protocol document: